Phaseline

Companies › Ocus Innovation Ireland

Ocus Innovation Ireland: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Ophthalmology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Atropine
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 3MyopiaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07028827AtropinePhase 3MyopiaOphthalmologyDec 2027
NCT07028827AtropinePhase 3MyopiaOphthalmologyDec 2027

Targets

CHRM3 (1) CHRM1 (1) CHRM2 (1)

Companies with the same targets

Bristol-Myers Squibb AstraZeneca Zhaoke (Guangzhou) Ophthalmology Pharmaceutical GSK Novartis Chiesi Farmaceutici Anavex Life Sciences ACADIA Pharmaceuticals NSC-Therapeutics

Companies built like this

ReGenTree Ocumension Therapeutics (Suzhou) Alkeus Pharmaceuticals Laboratorios Sophia S.A de C.V. Cloudbreak Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.